The biotechnology landscape is witnessing an unprecedented transformation as genetic engineering meets species conservation. Colossal Bioscience raised $120M in additional Series C funding, marking a pivotal moment where cutting-edge de-extinction technology converges with the world’s most critical conservation challenges. This groundbreaking investment signals a new era of genetic conservation excellence, where intelligent species revival revolutionizes biodiversity restoration across global ecosystems.

De-Extinction Pioneer Secures Historic $120M, Pushing Series C to $320M Total

Colossal Bioscience’s $120M funding extension represents the ultimate validation of de-extinction technology’s transformative potential in conservation biology. Colossal Bioscience has raised additional funding to supplement its $200M Series C, bringing the total round to $320M with participation from filmmaker Peter Jackson and other high-profile investors. The CEO confidently states the company expects to resurrect the dodo bird in less than seven years, demonstrating profound institutional confidence in genetic engineering platforms.

Harvard Geneticist & Billionaire Entrepreneur’s $10.3B Decacorn Achievement

The founder combination demonstrates EXTRAORDINARY scientific and business leadership convergence! Founded in 2021 by Harvard geneticist George Church and billionaire entrepreneur Ben Lamm, Colossal represents the perfect marriage of academic excellence and entrepreneurial execution. The company secured $200 million in Series C funding in January 2025, achieving $10.2 billion valuation and making it Texas’ first decacorn, while Ben Lamm’s net worth reached $3.7 billion through successful venture backing.

Revolutionary Genetic Engineering Platform: Woolly Mammoth by 2028, Dodo Revival Program

Colossal Bioscience stands as the definitive genetic engineering platform enabling species de-extinction through advanced reproductive technology and conservation biology applications. Dallas-based operations target woolly mammoth hybrid calves by 2028 for reintroduction to Arctic tundra habitats, while simultaneously leading research projects to release Tasmanian tiger joeys back to their natural environments. CEO Ben Lamm’s philosophy of “Why leave nature to chance?” drives pursuit of de-extinction goals backed by hundreds of millions from investors ranging from celebrities to intelligence agencies.

$435M Total Funding with Celebrity Investor Backing Creates Conservation Revolution

Colossal Bioscience’s funding achievement demonstrates EXTRAORDINARY market validation across diverse investor categories. As of January 2025, the company raised $435 million in total funding since foundation, with celebrity backing from filmmaker Peter Jackson representing mainstream appeal of de-extinction technology. This massive financial commitment validates that genetic engineering for species conservation represents transformational approach to biodiversity restoration with both scientific and commercial viability.

Global Expansion Strategy: From Texas Decacorn to International Genetic Engineering Leader

The Colossal Bioscience’s Series C funding extension accelerates global expansion beyond United States operations, with August 2025 acquisition of Thylacine Integrated Genetics marking first international expansion in genetic engineering capabilities. The new funding enables Colossal to expand artificial womb technology and de-extinction species programs, positioning the company for unprecedented leadership in conservation biotechnology across international markets while maintaining Texas headquarters as innovation center.

Colossal Bioscience raised $120M not just as funding, but as proof that genetic engineering conservation has arrived. The revolution is here, powered by authentic Harvard scientific expertise, proven billionaire entrepreneurship, and unwavering commitment to species revival excellence.

---

bUSINESS MODEL OF COLOSSAL BIOSCIENCE

CATEGORY	DETAILED ANALYSIS
HOW COLOSSAL BIOSCIENCE STARTED	HARVARD GENETICIST MEETS BILLIONAIRE ENTREPRENEUR! Founded in 2021 by Harvard geneticist George Church (de-extinction research pioneer) and billionaire entrepreneur Ben Lamm (serial startup founder) who recognized massive conservation gap in species restoration! Started with $15M initial funding to develop genetic engineering for woolly mammoth revival. Emerged from Church’s decades of genetic research combined with Lamm’s entrepreneurial execution capability. AUTHENTIC SCIENTIFIC EXPERTISE transformed into revolutionary conservation technology!
PRESENT CONDITION OF COLOSSAL BIOSCIENCE	TEXAS DECACORN WITH GLOBAL EXPANSION! Just secured additional $120M extending Series C to $320M total achieving $10.3B valuation! Total funding reaches $435M since 2021 with celebrity investors including Peter Jackson! Woolly mammoth by 2028, dodo revival by 2032 timeline established. International expansion through Thylacine Integrated Genetics acquisition. Ben Lamm $3.7B net worth! REAL GENETIC ENGINEERING, REAL SPECIES REVIVAL, REAL DECACORN!
FUTURE OF COMPANY & INDUSTRY	DE-EXTINCTION BIOTECHNOLOGY REVOLUTION! Company positioned for EXPLOSIVE GROWTH with species revival technology and artificial womb advancement under Harvard scientific leadership. Conservation industry desperately needs genetic engineering solutions—Colossal is THE PIONEER! Global expansion planned with international genetic capabilities. Market-defining positioning in conservation creates TRILLION-DOLLAR BIODIVERSITY TRANSFORMATION!
OPPORTUNITIES FOR YOUNG ENTREPRENEURS	CONSERVATION BIOTECHNOLOGY IS THE NEW FRONTIER! Massive opportunities in: Genetic engineering platforms, Artificial reproductive technology, Conservation genomics, Species restoration consulting, Biodiversity monitoring systems, Synthetic biology applications. Conservation industry starving for technological innovation—FIRST-MOVER ADVANTAGE across multiple biotechnology verticals!
MARKET SHARE	MONOPOLISTIC DE-EXTINCTION LEADER! Only company successfully pursuing large-scale species revival represents 100% market control in de-extinction biotechnology! Conservation market estimated $200B+ globally—Colossal positioned as CATEGORY CREATOR in genetic species restoration. $435M funding demonstrates unmatched investor confidence with celebrity backing validating mainstream appeal!
MOAT (COMPETITIVE ADVANTAGE)	IMPENETRABLE SCIENTIFIC FORTRESS! 1) Harvard Genetic Engineering Expertise—George Church’s decades of research creates technical barriers 2) Billionaire Entrepreneur Leadership—Ben Lamm’s $3.7B net worth ensures continued funding 3) Celebrity Investor Backing—Peter Jackson validates mainstream credibility 4) First-Mover Monopoly—only large-scale de-extinction company 5) International Expansion—global genetic capabilities create scale advantages! IMPOSSIBLE TO REPLICATE ADVANTAGE COMBINATION!
HOW COMPANY MAKES MONEY	CONSERVATION BIOTECHNOLOGY EMPIRE! Primary Revenue Streams: 1) Genetic Engineering Services—species restoration project contracts 2) Artificial Reproductive Technology—licensing to conservation organizations 3) Research Partnerships—collaboration with universities and governments 4) Conservation Consulting—biodiversity restoration strategy services 5) Intellectual Property Licensing—genetic engineering patents and technology transfer. HIGH-VALUE, SCALABLE BIOTECHNOLOGY MODEL!
KEY EVIDENCE	UNDENIABLE DE-EXTINCTION DOMINANCE: Additional $120M funding (Sept 2025) $435M total raised validates market confidence $10.3B decacorn valuation achieved Harvard geneticist co-founder = scientific credibility Peter Jackson celebrity investor confirms mainstream appeal Woolly mammoth 2028 timeline = concrete milestones International expansion through acquisitions = global reach!